logo-loader
viewCytoDyn Inc.

CytoDyn adds new talent to its management team

CytoDyn Inc (OTCMKST:CYDY) CEO Dr Nader Pourhassan and Dr Richard Pestell tell Proactive Investors the biotech has added two senior executives to its management team as it seeks regulatory approval of its flagship drug leronlimab (PRO 140) to treat cancer and HIV.

Dr Pestell added more insights and color into CytoDyn's recent announcement about beginning pre-clinical studies with leronlimab to treat Non-Alcoholic Steatohepatitis (NASH).

Quick facts: CytoDyn Inc.

Price: 3.14 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.51 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn continues to report strong results from COVID-19...

CytoDyn Inc (OTCQB: CYDY) President and CEO Nader Pourhassan and Bruce Patterson, M.D. and Chief Executive Officer and founder of IncellDx joined Steve Darling from Proactive Vancouver with news the company continues to see more impressive results from COVID-19 patients who have received...

3 weeks, 6 days ago

2 min read